MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Cancerology is booming and immunotherapy represents the most promising approach. At the APHM we have been at the forefront of these therapeutic advances and as a radiotherapist, I’m developing new strategies combining radiotherapy and immunotherapy to reach the « abscopal effect ». MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.#clinic
Together, we pursue a simple goal: to better understand the alterations of energetic metabolism in pancreatic cancer cells
AMU, IPC, CRCM
MI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate
As such, we are involved in the Marseille immunology biotope
MI should enable us to accelerate discovery, enhance our treatment options and offer more innovative options to our patients through current clinical trials and those of the future.